India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Palm Beach protests erupted as intensified immigration enforcement reached the heart of Trump’s hometown, while millions in Florida brace for rising health care costs as key subsidies near expiration. At the same time, state regulators boldly declare the long‑running property insurance crisis “over,” leaving homeowners and industry professionals questioning whether true stability has finally returned.
As 2025 comes to a close, the real estate industry is shifting from uncertainty to strategic expansion. According to DWS’s Year-End 2025 Outlook, property values are stabilizing after years of repricing, capital is concentrating on high-quality assets, and Sunbelt markets—especially Florida—continue to outperform. With technology enhancing rather than replacing professional expertise, 2026 is shaping up to reward professionals who stay informed, skilled, and strategically positioned for the next cycle.
Texas capital is pouring into San Francisco’s long‑struggling commercial real estate market, with Lone Star investors buying up discounted Union Square buildings and signaling what many experts believe is the city’s market bottom. As office activity and confidence begin to return, buyers from across the country are joining the rush, turning SF’s post‑pandemic slump into one of the nation’s hottest bargain opportunities.
With 2026 HousingWire Tech100 nominations closing on December 19, the housing tech sector is accelerating at full speed. AI‑powered data platforms, digital closing breakthroughs, embedded insurance growth, and next‑generation servicing automation are reshaping real estate, mortgage, insurance, and finance. From ATTOM’s AI‑ready property intelligence to Hapi Homes’ Martha Stewart design revival, Obie’s nationwide expansion, Outamation’s servicing automation, and ServiceLink’s next‑level borrower scheduling, this year’s standout innovators are defining the future of the housing economy.
Space Investment Partners has acquired the 123,402‑square‑foot Topanga Gateway retail center in Woodland Hills for $64 million, marking another significant move in the firm’s expanding grocery‑anchored investment strategy. Located at a high‑visibility intersection and 97% occupied at the time of sale, the property strengthens the company’s push toward $500 million to $1 billion in retail acquisitions for 2026, underscoring continued investor confidence in necessity‑based retail assets.
After the Federal Reserve’s final 2025 rate cut on December 10, mortgage markets are recalibrating, giving buyers and homeowners a glimmer of relief. Rates remain lower than earlier in the year, with 30-year fixed loans at 6.12% and refinances dipping as well. This shift may spark renewed activity for buyers, refinancers, and real estate professionals heading into 2026.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
